Although uncommon in NSCLC, KRAS focal amplification can act as an independent oncogenic driver and is linked to tumor progression and poor prognosis, while its influence on PD-1/PD-L1 inhibitor response remains unclear [22]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.